ATE481498T1 - Verfahren zur messung von neprilysinaktivität - Google Patents

Verfahren zur messung von neprilysinaktivität

Info

Publication number
ATE481498T1
ATE481498T1 AT03747225T AT03747225T ATE481498T1 AT E481498 T1 ATE481498 T1 AT E481498T1 AT 03747225 T AT03747225 T AT 03747225T AT 03747225 T AT03747225 T AT 03747225T AT E481498 T1 ATE481498 T1 AT E481498T1
Authority
AT
Austria
Prior art keywords
activity
neprilysin
measuring
present
expression
Prior art date
Application number
AT03747225T
Other languages
English (en)
Inventor
Takaomi Saido
Nobuhisa Iwata
Satoshi Tsubuki
Yoshie Takaki
Takashi Saito
Tadashi Nakaya
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE481498T1 publication Critical patent/ATE481498T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AT03747225T 2002-04-26 2003-04-24 Verfahren zur messung von neprilysinaktivität ATE481498T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002126257 2002-04-26
JP2002261250 2002-09-06
PCT/JP2003/005239 WO2003091449A1 (fr) 2002-04-26 2003-04-24 Methode de mesure de l'activite de la neprilysine

Publications (1)

Publication Number Publication Date
ATE481498T1 true ATE481498T1 (de) 2010-10-15

Family

ID=29272368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747225T ATE481498T1 (de) 2002-04-26 2003-04-24 Verfahren zur messung von neprilysinaktivität

Country Status (7)

Country Link
US (2) US7572574B2 (de)
EP (1) EP1500707B1 (de)
AT (1) ATE481498T1 (de)
AU (1) AU2003235113A1 (de)
CA (1) CA2483525C (de)
DE (1) DE60334200D1 (de)
WO (1) WO2003091449A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090023794A1 (en) * 2005-10-21 2009-01-22 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Sumoylation Inhibitors for the Treatment of Neurodegenerative Disease
US9097727B2 (en) 2010-03-03 2015-08-04 Kyoto University Method for diagnosing a protein misfolding disease using nerve cells derived from iPS cells
US9074238B2 (en) 2011-05-08 2015-07-07 Academia Sinica Methods for enhancing neprilysin activity and degrading amyloid-beta peptides and oligomers in a subject with Alzheimer's disease
JP7099717B2 (ja) * 2019-09-30 2022-07-12 株式会社理研バイオ ソマトスタチン受容体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04505556A (ja) * 1989-03-07 1992-10-01 シンジェン，インコーポレイテッド 細胞の検出または分離のための浮遊状態におけるインシトゥハイブリッド形成法
IE76319B1 (en) 1990-07-23 1997-10-22 Becton Dickinson Co Preservation of cells as controls or standards in cellular analysis
JP4175678B2 (ja) 1996-06-07 2008-11-05 武田薬品工業株式会社 新規ペプチド、その製造法および用途
CA2260376A1 (en) * 1999-02-11 2000-08-11 Universite De Montreal New metalloproteases of the neprilysin family

Also Published As

Publication number Publication date
US20090298775A1 (en) 2009-12-03
WO2003091449A1 (fr) 2003-11-06
DE60334200D1 (de) 2010-10-28
AU2003235113A1 (en) 2003-11-10
EP1500707A4 (de) 2007-05-09
US20060008842A1 (en) 2006-01-12
EP1500707A1 (de) 2005-01-26
AU2003235113A8 (en) 2003-11-10
EP1500707B1 (de) 2010-09-15
CA2483525C (en) 2013-01-22
US7572574B2 (en) 2009-08-11
CA2483525A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
ATE283485T1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
EP1302542A4 (de) Neues, physiologisch aktives peptid und dessen verwendung
ATE520981T1 (de) Diagnose und überwachung von krankheiten
EA200100053A1 (ru) Кальций (3s)тетрагидро-3-фуранил(1s,2r)-3-[[(4-аминофенил)сульфонил](изобутил)амино]-1-бензил-2-(фосфоноокси)пропилкарбамат
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
DE60239522D1 (de) Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
CY1108182T1 (el) Μεσα εντοπισμου του παθολογικου μετασχηματισμου της πρωτεϊνης app και εφαρμογες τους
NO20052992D0 (no) Markorproteiner for diagnostisering av leversykdom og fremgangsmate for diagnostisering av leversykdom.
DK2157192T3 (da) Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner)
ATE376428T1 (de) Metallkomplexverbindungen
ATE119936T1 (de) Zusammensetzungen und verfahren zur synthese und analyse von enkephalinase.
ATE390939T1 (de) In-vivo verfahren zur messung von auf der haut oder dessen komponenten bindenden aktiven chemischen substanzen
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
ATE310736T1 (de) Verbindungen zur bilddarstellung der alzheimer- krankenheit
DK0507831T3 (da) Fremgangsmåde til detektion af knogle- og bindevævssygdomme hos mennesker og dyr
ATE481498T1 (de) Verfahren zur messung von neprilysinaktivität
DK1791973T3 (da) DOT1-histonmethyltransferaser som et target til at identificere terapeutiske midler mod leukæmi
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
ATE275268T1 (de) Verfahren zur diagnose von sjögren-syndrom
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
DE602004011478D1 (de) Anzeige der genauigkeit einer quantitativen analyse
BRPI0515346A (pt) associação de polimorfismos protéicos com doenças coronárias do coração
DE60329500D1 (de) Verfahren zur identifikation von salzempfindlichen personen
ATE323288T1 (de) Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten
ATE428932T1 (de) Diagnostische verwendung von scn2b für alzheimer erkrankung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties